OTCMKTS:HKMPY Hikma Pharmaceuticals (HKMPY) Stock Price, News & Analysis $50.60 -1.47 (-2.82%) As of 03/31/2025 11:19 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHeadlinesShort InterestBuy This Stock About Hikma Pharmaceuticals Stock (OTCMKTS:HKMPY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Hikma Pharmaceuticals alerts:Sign Up Key Stats Today's Range$50.18▼$50.6250-Day Range$50.60▼$59.2652-Week Range$46.16▼$59.26Volume6,443 shsAverage Volume979 shsMarket CapitalizationN/AP/E Ratio16.35Dividend Yield0.63%Price TargetN/AConsensus RatingN/A Company OverviewHikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.Read More… Remove Ads Receive HKMPY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hikma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address HKMPY Stock News HeadlinesHikma Pharmaceuticals rallies Wednesday, outperforms marketMarch 19, 2025 | marketwatch.comHikma Pharmaceuticals (HIK) Receives a Buy from Berenberg BankMarch 12, 2025 | markets.businessinsider.comNew “Trump” currency proposed in DCAfter a massive run-up – tech stocks are crashing. And as you’d suspect, the rich and powerful got out first. Warren Buffett sold off 115 million shares of Apple last year.April 1, 2025 | Paradigm Press (Ad)Hikma looks to launch generic versions of Novo Nordisk diabetes drugs, FT saysMarch 10, 2025 | markets.businessinsider.comAxsome Therapeutics settles Sunosi patent litigation with HikmaMarch 5, 2025 | markets.businessinsider.comAxsome resolves patent dispute with HikmaMarch 5, 2025 | msn.comHikma Pharmaceuticals Full Year 2024 Earnings: Revenues Beat Expectations, EPS LagsFebruary 28, 2025 | finance.yahoo.comEmergent BioSolutions, Hikma enter partnership for sale of Kloxxado nasal sprayJanuary 14, 2025 | markets.businessinsider.comSee More Headlines HKMPY Stock Analysis - Frequently Asked Questions How have HKMPY shares performed this year? Hikma Pharmaceuticals' stock was trading at $50.0075 at the beginning of the year. Since then, HKMPY shares have increased by 1.2% and is now trading at $50.60. View the best growth stocks for 2025 here. How do I buy shares of Hikma Pharmaceuticals? Shares of HKMPY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Record date for 5/12 Dividend3/21/2025Ex-Dividend for 5/12 Dividend3/21/2025Today4/01/2025Dividend Payable5/12/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolOTCMKTS:HKMPY CIKN/A Webwww.hikma.com Phone442073992760FaxN/AEmployees9,100Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio16.35 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (OTCMKTS:HKMPY) was last updated on 4/1/2025 by MarketBeat.com Staff From Our PartnersNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredNew “Trump” currency proposed in DCA former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | SponsoredLive Footage From Elon Musk’s “Area 51”What’s happening inside this nondescript building in South Memphis is so incredible… That Elon’s competitor...Brownstone Research | SponsoredTermination: 18F (read immediately)Have you ever heard of the government's 18F program? It helped manage digital services across the governmen...Altimetry | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | Sponsored“Massive Financial Reset Is Coming”The U.S. markets will see a massive reset, beginning days from now. But the "reset" isn't what you might ex...InvestorPlace | SponsoredGold Hits $3,000… Here’s How You Can Get More for Under $20With gold surging to record highs, currently trading above $3,000 an ounce, and central banks aggressively sto...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hikma Pharmaceuticals PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Hikma Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.